)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Celyad Oncology
Celyad Oncology (CYAD) investor relations material
Celyad Oncology H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary23 Sep, 2026
Executive summary
Focus shifted to monetizing intellectual property after discontinuing R&D and clinical trials in 2022, with efforts to secure licensing or asset sale agreements.
Sale of the C-CathEZ catheter business to CellProthera completed in February 2026, with up to €5 million in milestone-based payments and future royalties.
Private placement of €0.5 million in July 2026 extended cash runway to mid Q2 2027.
Financial highlights
Net loss for H1 2026 was €1.2 million, a significant improvement from €3.7 million in H1 2025.
Operating loss for H1 2026 was €1.2 million, compared to €3.7 million in H1 2025.
Cash and cash equivalents stood at €0.1 million as of June 30, 2026, down from €1.7 million at year-end 2025.
Employee benefit expenses dropped to €0.4 million due to workforce reduction.
Other income increased due to gain on sale of the C-Cath business.
Outlook and guidance
Cash runway extended to mid Q2 2027 following the July 2026 private placement.
Additional funding required by mid Q2 2027; company is evaluating financing options including equity, debt, partnerships, or asset sales.
No assurance of securing further financing, indicating material uncertainty about going concern status.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Celyad Oncology
- Returned to profitability in 2025 via asset sales, but future depends on IP monetization and new funding.CYAD
H2 2025 - Net loss widened to €3.7M in H1 2025, with cash projected to last into Q4 amid ongoing risks.CYADH1 2025
- Net loss narrowed and cash runway secured as CAR T-cell platforms advance and partnerships pursued.CYADH1 2024
- Net loss narrowed and cash burn reduced as Celyad advanced CAR-T platforms but faces funding risks.CYADH2 2024
Next Celyad Oncology earnings date
H2 20261 Apr, 2027
Celyad Oncology
Next Celyad Oncology earnings date
H2 20261 Apr, 2027
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage